Retinal Tissue Production via BMP and CHK1 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing retinal tissue from pluripotent stem cells result in varying quality and a significant proportion of non-target cells, which is undesirable for transplantation purposes.
Innovation Solution
A method involving the combination of BMP signaling pathway agonists and CHK1 signaling pathway inhibitors, specifically using PD407824, to reduce the concentration of BMP and enhance the differentiation of pluripotent stem cells into retinal tissue, producing a sphere-like cell aggregate with a reduced proportion of non-target cells and a favorable multilayer structure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BMP signaling pathway agonist is used to differentiate pluripotent stem cells into retinal tissue, then retinal tissue can be produced, but the proportion of non-target cells increases and quality varies
Solution Approach 1:
The patent applies parameter changes by combining BMP signaling pathway agonist with CHK1 signaling pathway inhibitor to modify the differentiation process. This combination changes the cellular response parameters, enabling precise control over retinal tissue differentiation while suppressing non-target cell formation, thereby improving tissue quality and reducing harmful non-target cells.
Solution Approach 2:
The CHK1 signaling pathway inhibitor acts as an intermediary substance that modulates the BMP signaling pathway's effect. By introducing this intermediary agent, the patent achieves enhanced control over the differentiation process, improving the proportion of target retinal cells while suppressing non-target cell generation.
2Productivity
If typical concentration of BMP is used for differentiation, then retinal tissue can be formed, but the concentration required is high and efficiency is reduced
Solution Approach 1:
The patent changes the parameter of BMP concentration requirement by combining it with CHK1 signaling pathway inhibitor. This combination enables effective retinal tissue differentiation at much lower BMP concentrations (about 1/10 of typical concentration), significantly improving production efficiency while reducing substance quantity requirements.
Solution Approach 2:
The CHK1 signaling pathway inhibitor serves as a mediator that enhances BMP signaling efficiency. This intermediary agent allows the system to achieve the same differentiation effect with reduced BMP concentration, thereby improving productivity and reducing material requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively produces retinal tissue with a lower proportion of non-target cells and a predetermined shape, improving the quality and efficiency of retinal tissue production for potential use in transplantation.
Implementation Method 1
suspension-culturing the cell aggregate obtained in the step (A) in the presence of a BMP signaling pathway agonist and a CHK1 signaling pathway inhibitor to obtain a cell aggregate containing a retinal cell
Data Source
AI summary
An object of the present invention is to provide a method for producing a retinal cell or retinal tissue with a reduced proportion of non-target cells in differentiating pluripotent stem cells. The method of the present invention for producing a retinal cell or retinal tissue comprises: (A) suspension-culturing a pluripotent stem cell to form a cell aggregate of pluripotent stem cells; and (B) suspension-culturing the cell aggregate obtained in the step (A) in the presence of a BMP signaling pathway agonist and a CHK1 signaling pathway inhibitor to obtain a cell aggregate containing a retinal cell.